Thaumaturgo N, Vilar M M, Diogo C M, Edelenyi R, Tendler M
Laboratório de Esquistossomose Experimental, Departamento de Helmintologia, Instituto Oswaldo Cruz, Fiocruz, Rio de Janeiro, RJ, 21045-900, Brasil.
Mem Inst Oswaldo Cruz. 2001;96 Suppl:79-83. doi: 10.1590/s0074-02762001000900011.
In previous studies it was shown that the recombinant molecule, r-Sm14, induces high levels of protection against Schistosoma mansoni infection in two outbred animal models and immune crossprotection against infection by Fasciola hepatica in Swiss outbred mice. r-Sm14 was derived from a living worm extract, called SE, and is being developed as the molecular basis of an anti-helminth bivalent vaccine against the two parasites, for medical and veterinary application. Present data refer to SDS-PAGE and Western Blotting analysis of four different preparations of S. mansoni adult worms focusing Sm14 identification. The extracts correspond to the initial fraction of the SE extraction process, containing products released by living worms (SEi); SE2, reextraction of adult worms in PBS; and SE of separated male and female adult worms. In all extracts it was possible to detect the component of 14 kDa, that was recognized by specific anti-rSm14 antibody raised in rabbits.
在先前的研究中表明,重组分子r-Sm14在两种远交动物模型中诱导出高水平的针对曼氏血吸虫感染的保护作用,并且在瑞士远交小鼠中诱导出针对肝片吸虫感染的免疫交叉保护作用。r-Sm14源自一种名为SE的活虫提取物,正作为一种针对这两种寄生虫的抗蠕虫二价疫苗的分子基础进行研发,用于医学和兽医学应用。目前的数据涉及对四种不同曼氏血吸虫成虫制剂的SDS-PAGE和蛋白质印迹分析,重点是Sm14的鉴定。提取物对应于SE提取过程的初始部分,包含活虫释放的产物(SEi);SE2,成虫在PBS中的再提取;以及分离的雌雄成虫的SE。在所有提取物中都能检测到14 kDa的成分,它能被在兔体内产生的特异性抗rSm14抗体识别。